Literature DB >> 11907706

Alendronate disturbs vesicular trafficking in osteoclasts.

A Alakangas1, K Selander, M Mulari, J Halleen, P Lehenkari, J Mönkkönen, J Salo, Kalervo Väänänen.   

Abstract

The nitrogen-containing bisphosphonate alendronate inhibits osteoclast-mediated bone resorption through inhibition of the mevalonate pathway. This results in impaired protein prenylation and may affect the function of small GTPases in osteoclasts. Since these proteins are important regulators of vesicle transport in cells, we investigated the possible interference of alendronate with these processes in isolated rat osteoclasts. We show here that alendronate-induced inhibition of bone resorption coincides with accumulation of tartrate-resistant acid phosphatase- and electron dense material-containing tubular vesicles in osteoclasts. Alendronate-induced changes in osteoclasts also included widening of the sealing zone areas and incomplete organization of tight attachments and ruffled borders. Osteoclasts also appeared partially detached from the bone surface, and organic matrix was typically dissolved only at the edges of the resorption pits on alendronate-coated bone slices. In contrast, resorption pits on the control and clodronate-coated bone slices were thoroughly resorbed. Inhibition of bone resorption by alendronate was not, however, related to a decrease in osteoclast number. In conclusion, our findings suggest that alendronate inactivates osteoclasts by mechanisms that impair their intracellular vesicle transport, apoptosis being only a secondary phenomenon to this.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11907706     DOI: 10.1007/s002230010047

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  19 in total

1.  Circulating microRNA signature of steroid-induced osteonecrosis of the femoral head.

Authors:  Zheng Li; Chao Jiang; Xingye Li; William K K Wu; Xi Chen; Shibai Zhu; Chanhua Ye; Matthew T V Chan; Wenwei Qian
Journal:  Cell Prolif       Date:  2017-12-04       Impact factor: 6.831

2.  Expert opinion 2011 on the use of new anti-resorptive agents in the prevention of skeletal-related events in metastatic bone disease.

Authors:  Rodica Anghel; Alexander Bachmann; Meral Bekşac; Thomas Brodowicz; Jindřich Finek; Radko Komadina; Krzysztof Krzemieniecki; Istvan Lang; Jozef Marencak; Roger von Moos; Martin Pecherstorfer; Tamara Rordorf; Damir Vrbanec; Christoph Zielinski
Journal:  Wien Klin Wochenschr       Date:  2013-07-06       Impact factor: 1.704

3.  Minodronic acid induces morphological changes in osteoclasts at bone resorption sites and reaches a level required for antagonism of purinergic P2X2/3 receptors.

Authors:  Makoto Tanaka; Akihiro Hosoya; Hiroshi Mori; Ryoji Kayasuga; Hiroaki Nakamura; Hidehiro Ozawa
Journal:  J Bone Miner Metab       Date:  2017-02-27       Impact factor: 2.626

4.  Effects of drug discontinuation after short-term daily alendronate administration on osteoblasts and osteocytes in mice.

Authors:  Kanako Tsuboi; Tomoka Hasegawa; Tomomaya Yamamoto; Muneteru Sasaki; Hiromi Hongo; Paulo Henrique Luiz de Freitas; Tomohiro Shimizu; Masahiko Takahata; Kimimitsu Oda; Toshimi Michigami; Minqi Li; Yoshimasa Kitagawa; Norio Amizuka
Journal:  Histochem Cell Biol       Date:  2016-05-27       Impact factor: 4.304

Review 5.  Mechanism of action of bisphosphonates.

Authors:  Alfred A Reszka; Gideon A Rodan
Journal:  Curr Osteoporos Rep       Date:  2003-09       Impact factor: 5.096

6.  Localization of Minodronate in Mouse Femora Through Isotope Microscopy.

Authors:  Hiromi Hongo; Muneteru Sasaki; Sachio Kobayashi; Tomoka Hasegawa; Tomomaya Yamamoto; Kanako Tsuboi; Erika Tsuchiya; Tomoya Nagai; Naznin Khadiza; Miki Abe; Ai Kudo; Kimimitsu Oda; Paulo Henrique Luiz de Freitas; Minqi Li; Hisayoshi Yurimoto; Norio Amizuka
Journal:  J Histochem Cytochem       Date:  2016-10       Impact factor: 2.479

7.  Intravenous ibandronate rapidly reduces pain, neurochemical indices of central sensitization, tumor burden, and skeletal destruction in a mouse model of bone cancer.

Authors:  Kyle G Halvorson; Molly A Sevcik; Joseph R Ghilardi; Lucy J Sullivan; Nathan J Koewler; Frieder Bauss; Patrick W Mantyh
Journal:  J Pain Symptom Manage       Date:  2008-04-14       Impact factor: 3.612

8.  Zoledronic acid concurrent with either high- or reduced-dose palliative radiotherapy in the management of the breast cancer patients with bone metastases: a phase IV randomized clinical study.

Authors:  Lale Atahan; Ferah Yildiz; Mustafa Cengiz; Bunyamin Kaplan; Metin Ozkan; Gozde Yazici; Mete Gündoğ; Ayfer Haydaroğlu; Aylin F Korcum; Meriç Sengöz; Maktav Dinçer; Müge Akmansu; Kayihan Engin; Mutlu Hayran
Journal:  Support Care Cancer       Date:  2009-05-31       Impact factor: 3.603

9.  Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis?

Authors:  Leila Kolios; Ann Kristin Hoerster; Stephan Sehmisch; Marie Christin Malcherek; Thomas Rack; Mohammed Tezval; Dana Seidlova-Wuttke; Wolfgang Wuttke; Klaus Michael Stuermer; Ewa Klara Stuermer
Journal:  Calcif Tissue Int       Date:  2009-12-01       Impact factor: 4.333

10.  Zoledronic Acid Deteriorates Soft and Hard Tissue Healing of Murine Tooth Extraction Sockets in a Dose-Dependent Manner.

Authors:  Ryohei Kozutsumi; Shinichiro Kuroshima; Haruka Kaneko; Muneteru Sasaki; Akira Ishisaki; Takashi Sawase
Journal:  Calcif Tissue Int       Date:  2021-08-07       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.